반려동물용 약제 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 동물별, 적응증별, 유통 채널별, 지역별, 부문 예측(2025-2034년)

Companion Animal Medicine Market Growth & Trends:

The global companion animal medicine market size is expected to reach USD 66.96 billion by 2034 and is expected to expand at 11.14% CAGR from 2025 to 2034, according to a new report by Grand View Research, Inc. The key factors driving the growth of the market for companion animal medicine include the rising pet population, the increased prevalence of diseases, and the availability of pet insurance.

In Canada for example, more than half of the country's households (around 60% of households) owned at least one dog or cat in 2022, according to the Canadian Animal Health Institute (CAHI). The country's dog population increased from 7.7 million in 2020 to 7.9 million in 2022, whereas the cat population increased from 8.1 million in 2020 to 8.5 million in 2022. CAHI also reported a surge in feline vet visits following the start of the COVID-19 outbreak in 2020.

The COVID-19 pandemic notably affected the market for companion animal medicine. The impact included dampened sales, supply chain challenges, operational hurdles, falling inpatient visits, and reduced demand. Elanco for instance reported a 20% decline in revenue during Q2 2020. The company's companion animal segment, in particular, was adversely impacted by the fall in brands in international markets and those administered in the clinic e.g. vaccines.

The company reported a recovery in sales during H2 2020. Vetoquinol on the other hand reported an increase in sales, driven by its essential portfolio including veterinary drugs in 2020 despite limited access to vet clinics and hospitals due to lockdown protocols. Boehringer Ingelheim too registered increased sales in the companion animal segment.

With the rising number of pets across the globe, the trend of pet humanization has gained traction in several key markets. Pet guardians are becoming increasingly aware of their pet's health, treatment, and well-being. This has increased the adoption of pet insurance to reduce the financial risks for them. Petplan- the largest pet insurance provider in the U.K. offers insurance policies for various species including dogs, cats, horses, small mammals, birds, reptiles, rabbits, and multi-pet owners. These policies provide coverage for physical and online consultations, prescription medicine, diagnostic tests, surgery, dental injury, cancer treatment, and more.

The rising prevalence of diseases in pets is another key driver expected to contribute to market growth. Parasitic infections from internal and external parasites for example, commonly affect pets. Antibiotics and topical therapies are often prescribed in the case of pyoderma. However, further testing and routine bathing with medicated shampoos may be prescribed in case of chronic or recurring pyoderma. For example, Viv Silky Shampoo by Vivaldis is indicated for various fungal and bacterial infections including superficial and deep pyoderma.

Companion Animal Medicine Market Report Highlights:

• The pharmaceuticals segment held the largest market share of 59.53% in 2024. The pharmaceuticals segment for companion animals includes various products to treat multiple health conditions.
• The dog segment within the companion animal medicine industry is experiencing robust growth, driven by widespread pet ownership, increasing veterinary healthcare spending, and the growing availability of medicines designed for canine conditions.
• The infectious diseases segment dominated the global companion animal medicine in 2024, driven by the growing burden of transmissible diseases and heightened focus on preventive care.
• The hospital pharmacy segment dominated the market by distribution channel in 2024. The factors contributing to the large share include higher patient footfalls at hospitals and the convenience of buying the necessary medications as soon as the pet is diagnosed
• North America region dominated the market in 2024 and registered the largest revenue share of over 36.04%. This is due to the region's high per capita animal healthcare spending and a large number of pet owners

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definition
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
• 1.6. Market Formulation & Visualization
• 1.7. Data Validation & Publishing
• 1.8. Model Details
  • 1.8.1. Commodity flow analysis
  • 1.8.2. Global Market: CAGR Calculation
• 1.9. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. North America Companion Animal Medicine Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rapid Advancements in the Field of Companion Animal Medicine
    • 3.2.1.2. Increasing Humanization of Pets & Expenditure on Pets
    • 3.2.1.3. Support Initiatives
    • 3.2.1.4. Changing Pet Demographics Globally
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Emergence of Adverse Drug Reactions (ADR)
    • 3.2.2.2. Complex Regulations
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
  • 3.2.5. Industry Analysis - Porter's
    • 3.2.5.1. Bargaining power of the suppliers
    • 3.2.5.2. Bargaining power of the buyers
    • 3.2.5.3. Threats of substitution
    • 3.2.5.4. Threats from new entrants
    • 3.2.5.5. Competitive rivalry
  • 3.2.6. PESTEL Analysis
    • 3.2.6.1. Political landscape
    • 3.2.6.2. Economic and Social landscape
    • 3.2.6.3. Technological landscape
• 3.3. Pricing Analysis, by Product
• 3.4. Regulatory framework
• 3.5. Product Pipeline Analysis
• 3.6. COVID-19 Impact Analysis
• 3.7. Estimated Disease Prevalence Analysis by Key Species

Chapter 4. Global Companion Animal Medicine Market: By Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Companion Animal Medicine Market: By Product Movement Analysis, 2024 & 2034 (USD Million)
  • 4.2.1. Biologics
    • 4.2.1.1. Biologics Market Estimates And Forecasts, 2018 - 2034 (USD Million)
    • 4.2.1.2. Vaccines
      • 4.2.1.2.1. Vaccines Market Estimates And Forecasts, 2018 - 2034 (USD Million)
      • 4.2.1.2.2. Modified/ Attenuated Live
        • 4.2.1.2.2.1. Modified/ Attenuated Live Market Estimates And Forecasts, 2018 - 2034 (USD Million)
      • 4.2.1.2.3. Inactivated (Killed)
        • 4.2.1.2.3.1. Inactivated (Killed) Market Estimates And Forecasts, 2018 - 2034 (USD Million)
      • 4.2.1.2.4. Other Vaccines
        • 4.2.1.2.4.1. Other Vaccines Market Estimates And Forecasts, 2018 - 2034 (USD Million)
    • 4.2.1.3. Other Biologics
      • 4.2.1.3.1. Other Biologics Market Estimates And Forecasts, 2018 - 2034 (USD Million)
      • 4.2.1.3.2. Monoclonal Antibody (mAb)
        • 4.2.1.3.2.1. Monoclonal Antibody (mAb) Market Estimates And Forecasts, 2018 - 2034 (USD Million)
        • 4.2.1.3.2.2. Dogs
          • 4.2.1.3.2.2.1. Dogs Market Estimates And Forecasts, 2018 - 2034 (USD Million)
        • 4.2.1.3.2.3. Cats
          • 4.2.1.3.2.3.1. Cats Market Estimates And Forecasts, 2018 - 2034 (USD Million)
      • 4.2.1.3.3. Other Biologics (excluding mAb)
        • 4.2.1.3.3.1. Other Biologics (excluding mAb) Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 4.2.2. Pharmaceuticals
    • 4.2.2.1. Pharmaceuticals Market Estimates And Forecasts, 2018 - 2034 (USD Million)
    • 4.2.2.2. Parasiticides
      • 4.2.2.2.1. Parasiticides Market Estimates And Forecasts, 2018 - 2034 (USD Million)
    • 4.2.2.3. Anti-infectives
      • 4.2.2.3.1. Anti-infectives Market Estimates And Forecasts, 2018 - 2034 (USD Million)
    • 4.2.2.4. Anti-inflammatory
      • 4.2.2.4.1. Anti-inflammatory Market Estimates And Forecasts, 2018 - 2034 (USD Million)
    • 4.2.2.5. Other Pharmaceuticals
      • 4.2.2.5.1. Other Pharmaceuticals Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 4.2.3. Medicated Feed Additives
    • 4.2.3.1. Medicated Feed Additives Market Estimates And Forecasts, 2018 - 2034 (USD Million)

Chapter 5. Global Companion Animal Medicine Market: By Animal Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Companion Animal Medicine Market: By Animal Movement Analysis, 2024 & 2034 (USD Million)
  • 5.2.1. Dogs
    • 5.2.1.1. Dogs Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 5.2.2. Cats
    • 5.2.2.1. Cats Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 5.2.3. Horses
    • 5.2.3.1. Horses Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 5.2.4. Other Animals
    • 5.2.4.1. Other Animals Market Estimates And Forecasts, 2018 - 2034 (USD Million)

Chapter 6. Global Companion Animal Medicine Market: By Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Companion Animal Medicine Market: By Indication Movement Analysis, 2024 & 2034 (USD Million)
  • 6.2.1. Infectious Diseases
    • 6.2.1.1. Infectious Diseases Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 6.2.2. Dermatologic Diseases
    • 6.2.2.1. Dermatologic Diseases Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 6.2.3. Pain
    • 6.2.3.1. Pain Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 6.2.4. Orthopedic Diseases
    • 6.2.4.1. Orthopedic Diseases Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 6.2.5. Behavioral Diseases
    • 6.2.5.1. Behavioral Diseases Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 6.2.6. Other Indications
    • 6.2.6.1. Other Indications Market Estimates And Forecasts, 2018 - 2034 (USD Million)

Chapter 7. Global Companion Animal Medicine Market: By Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Companion Animal Medicine Market: By Distribution Channel Movement Analysis, 2024 & 2034 (USD Million)
  • 7.2.1. Retail
    • 7.2.1.1. Retail Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 7.2.2. E-commerce
    • 7.2.2.1. E-commerce Market Estimates And Forecasts, 2018 - 2034 (USD Million)
  • 7.2.3. Hospital/ Clinic Pharmacy
    • 7.2.3.1. Hospital/ Clinic Pharmacy Market Estimates And Forecasts, 2018 - 2034 (USD Million)

Chapter 8. Global Companion Animal Medicine Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2034
• 8.2. Regional Market Dashboard
• 8.3. Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2034:
• 8.5. North America
  • 8.5.1. North America market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.5.2. U.S.
    • 8.5.2.1. U.S. market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Canada market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Mexico market estimates and forecasts 2018 to 2034 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.6.2. UK
    • 8.6.2.1. UK market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Germany market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. France market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Italy market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Spain market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.6.7. Norway
    • 8.6.7.1. Norway market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Sweden market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.6.9. Denmark
    • 8.6.9.1. Denmark market estimates and forecasts 2018 to 2034 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.7.2. Japan
    • 8.7.2.1. Japan market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.7.3. China
    • 8.7.3.1. China market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.7.4. India
    • 8.7.4.1. India market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.7.5. Australia
    • 8.7.5.1. Australia market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.7.6. South Korea
    • 8.7.6.1. South Korea market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Thailand market estimates and forecasts 2018 to 2034 (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.8.2. Brazil
    • 8.8.2.1. Brazil market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Argentina market estimates and forecasts 2018 to 2034 (USD Million)
• 8.9. MEA
  • 8.9.1. MEA market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.9.2. South Africa
    • 8.9.2.1. South Africa market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Saudi Arabia market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. UAE market estimates and forecasts 2018 to 2034 (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Kuwait market estimates and forecasts 2018 to 2034 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Participant Categorization
• 9.2. Company Market Position Analysis/ Heat Map Analysis
• 9.3. Company Profile
  • 9.3.1. Merck & Co., Inc.
    • 9.3.1.1. Company overview
    • 9.3.1.2. Financial performance
    • 9.3.1.3. Product benchmarking
    • 9.3.1.4. Strategic initiatives
  • 9.3.2. Ceva
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Vetoquinol
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Zoetis
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Boehringer Ingelheim International GmbH
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Elanco Animal Health Incorporated
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Ourofino Animal Health
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Virbac
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Phibro Animal Health Corporation
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Dechra Pharmaceuticals Plc
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Bimeda Inc.
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
• 9.4. Strategy Mapping
  • 9.4.1. Mergers & Acquisitions
  • 9.4.2. Partnerships & Collaborations
  • 9.4.3. Expansion
  • 9.4.4. Product launch
  • 9.4.5. Others
• 9.5. List of other Key players